Please login to the form below

Not currently logged in
Email:
Password:

selumetinib

This page shows the latest selumetinib news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

It has assumed greater importance for the targeted pipeline – which sits alongside AZ’s immuno-oncology R&D – since MEK Inhibitor selumetinib failed late-stage trials in thyroid cancer and lung

Latest news

More from news
Approximately 3 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    But now hopes are high for two late-stage drugs: olaparib and selumetinib. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics